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Abstract
Studies of viral suppression on first-line antiretroviral therapy (ART) in persons living with
human immunodeficiency virus (PLHIV) in Haiti are limited, particularly among PLHIV out-
side of the Ouest department, where the capital Port-au-Prince is located. This study
described the prevalence and risk factors for delayed viral suppression among PLHIV in all
geographic departments of Haiti between 2013 and 2017. Individuals who received viral
load testing 3 to 12 months after ART initiation were included. Data on demographics and
clinical care were obtained from the Haitian Active Longitudinal Tracking of HIV database.
Multivariable logistic regression was performed to predict delayed viral suppression, defined
as a viral load�1000 HIV-1 RNA copies/mL after at least 3 months on ART. Viral load test
results were available for 3,368 PLHIV newly-initiated on ART. Prevalence of delayed viral
suppression was 40%, which is slightly higher than previous estimates in Haiti. In the multi-
variable analysis, delayed viral suppression was significantly associated with younger age,
receiving of care in the Ouest department, treatment with lamivudine (3TC), zidovudine
(AZT), and nevirapine (NVP) combined ART regimen, and CD4 counts below 200 cells/
mm3. In conclusion, this study was the first to describe and compare differences in delayed
viral suppression among PLHIV by geographic department in Haiti. We identified popula-
tions to whom public health interventions, such as more frequent viral load testing, drug
resistance testing, and ART adherence counseling should be targeted.
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Introduction
Careful adherence to effective antiretroviral therapy (ART) for people living with human immu-
nodeficiency virus (PLHIV) leads to suppression of plasma viral loads to undetectable levels.
Delays in viral suppression can lead to virologic failure, formally defined by the World
Health Organization (WHO) in developing countries as the failure to achieve a plasma viral
load level below 1,000 HIV-1 RNA copies/mL after three months on ART [1]. Virologic failure
is associated with higher rates of mortality, immunosuppression and the accumulation of resis-
tance mutations [2, 3] and individuals who are not suppressed have a much higher probability
of transmitting the virus to others [3].
Haiti has the highest adult HIV prevalence in the Western hemisphere [4]. Despite this, few
studies have characterized the viral suppression status of PLHIV in this population [5]. Viral
load assessments were introduced in five HIV care facilities in Haiti as part of a pilot program
in 2013 and were officially scaled-up nationally in 2016 [6]. Previous studies conducted among
clinics located in the capital of Port-au-Prince reported virologic failure prevalence estimates
between 32% and 51% [6, 7]. Factors associated with virologic failure in one study included
male sex, lower CD4 (<500 cells/mm3), poor adherence to ART, and tuberculosis co-infection
[6]. Major drug regimen changes–an indicator of failing drug therapies suggestive of virologic
failure–have also been assessed in Haiti, with another study reporting positive associations
with female sex, younger adult age (20–39 years old), ART initiation year after 2006, and lower
CD4 (<350 cells/mm3) at ART initiation [8]. To date, few studies have assessed the virologic
outcomes of PLHIV newly-initiated on ART or who reside outside of Port-au-Prince. The
aims of this study were to 1) estimate the prevalence of delayed viral suppression among
PLHIV recently initiated on ART in Haiti and 2) determine key demographic, geographic and
clinical characteristics associated with delayed viral suppression. We hypothesized that the
likelihood of delayed viral suppression varies according to demographic and clinical risk and
protective factors informed by the socio-ecologic model [9].
Methods
Study population
We employed a retrospective cohort design to assess the virologic outcomes of treatment naïve
PLHIV individuals newly-initiated on ART in Haiti. Data were accessed using the national
HIV case-based surveillance system, the Haitian Active Longitudinal Tracking of HIV data-
base (SALVH, French acronym), which has been operated by the Ministry of Public Health
and Population (MSPP) since 2008 and previously described elsewhere [5, 10]. Briefly, there
are three main health networks that provide treatment services to PLHIV in Haiti and report
electronic medical records (EMR) to SALVH, including the MSPP-affiliated clinics using the
iSanté EMR network (administered by the International Training and Education Center for
Health), the Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections
(GHESKIO), and Partners in Health’s Zanmi Lasante (PIH) [10]. For this analysis, we included
all PLHIV who received their first ART prescription between January 1, 2013 and December
31, 2016 and who had a viral load test performed between 3–12 months (90–365 days) after
ART initiation recorded in SALVH. Laboratory data were collected until December 31, 2017
to permit a full year of follow-up for all participants.
Ethics approval
This study was reviewed by, and received ethics approval from, the National Bioethics Com-
mittee in Haiti (reference: 1718–37) and the Institutional Review Board at the University of
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database is the Haitian Active Longitudinal Tracking
of HIV database (SALVH). The variables needed to
replicate the analysis are: age at HIV diagnosis,
sex, marital status, clinic commune, HIV diagnosis
year, World Health Organization clinical stage, ART
regimen, ART initiation date, CD4 and viral load
tests and test dates, and history or presence of
tuberculosis or sexually transmitted infections.
Funding: This work was supported by a grant
(ID00017061) from the National Alliance of State
and Territorial AIDS Directors to CD. There was no
additional external funding received for this study.
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Competing interests: The authors have declared
that no competing interests exist.
Florida (reference: IRB201702830). We received a full waiver of informed consent and the study
was approved as expedited since the data were collected originally for non-research purposes.
Delayed viral suppression
In Haiti’s pilot phase of viral load testing roll-out (July 2013 –October 2016), plasma blood
samples were collected at clinic facilities and transported to the National Public Health Labora-
tory (PNLS, French acronym) in Port-au-Prince where viral load levels were accessed using
the Generic HIV Viral Load Assay (Biocentric, Bandol, France). This test has a limit of detec-
tion of 300 copies/mL and detailed methods regarding its use in this population have previ-
ously been described elsewhere [6]. Starting after October 2016, dried blood spot (DBS)
analyses (limit of detection = 550–1000 copies/mL) [11] were introduced using the Abbott
Real-Time HIV-1 assay. The performance of DBS analysis for viral load monitoring is compa-
rable to plasma viral load monitoring and is recommended in low resource environments
where capacity for plasma storage and sample processing is limited [11, 12]. Briefly, 75ul of
whole blood was collected from each patient by a trained lab technician at each facility. Five
blood spots were applied to DBS filter paper strips and dried at room temperature for four
hours on a drying rack. The DBS samples were stored individually in a ziplocked envelope
containing desiccants and a humidity indicator card. Envelopes were transported twice weekly
to PNLS for viral load assessment. PLHIV with a viral load test result�1,000 HIV-1 RNA cop-
ies/mm3 between 3 to 12 months after ART initiation were classified as having delayed viral
suppression. PLHIV whose viral load test result was <1,000 copies/mm3 were classified as
virally suppressed. In the event a patient had more than one viral load test performed in the 3-
12-month window after ART initiation, we selected the earliest test result for the analysis.
Predictors
Candidate risk and protective factors were accessed at the time of the initial HIV case report and
included age, sex, marital status, and geographic department of clinic (Haiti is administratively
organized into 10 geographic departments). An individual’s clinical characteristics included dates
of HIV diagnosis and ART initiation, time from diagnosis to ART initiation (termed “time to
ART”), earliest recorded CD4 T-cell count (cells/mm3), ART drug regimen (combinations of
three possible drugs, including one non-nucleoside reverse transcriptase (NNRTI): nevirapine
[NVP] or efavirenz [EFV] and two nucleoside-reverse transcriptase inhibitors [NRTIs]: lamivu-
dine [3TC], zidovudine [AZT], or tenofovir [TDF]; or “other” if the regimen comprised less than
three medications or contained other less-frequently prescribed medications), WHO clinical stage
of HIV disease (scale of 1 to 4, where 4 is the most severe) [13], transmission risk factors identified
on the HIV case-report form, history or presence of tuberculosis (TB) or sexually transmitted
infections (STIs), and whether individuals received ART from one or multiple clinics during the
study period (termed “multiple treatment facilities”). Individuals with missing data on age, sex,
clinic department, dates of diagnosis and ART initiation, or ART regimen were excluded from
the inferential analyses. Large numbers of missing values in other covariates were categorized as
“unknown” or “missing” and retained for the regression analysis.
Statistical analysis
First, we described the frequency of viral load testing and frequency of delayed viral suppres-
sion among those tested. Demographic and clinical characteristics of individuals with and
without delayed viral suppression were compared using the chi-squared test for categorical
variables and two sample t-tests for age as a continuous variable. Variables that were signifi-
cantly different (p<0.05) by virologic status were examined in bivariate analyses and then
PLOS ONE Virologic suppression in Haiti
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included in the logistic regression analysis. The full model included: age (years), sex (male or
female [reference]), marital status (cohabiting, married, or divorced/widowed, single [refer-
ence]), and clinic department of location (Ouest [reference], Artibonite-Centre, Nord-Est,
Nord-Ouest, Sud [includes Sud, Sud-Est, Grande-Anse, and Nippes], or Nord) as well as clini-
cal factors: year of HIV diagnosis (<2010 [reference], 2010–11, 2012–13, 2014–15, 2016),
WHO clinical stage (I [reference], II, III, or IV), year of ART initiation (2013 [reference],
2014, 2015, or 2016), first-line ART regimen (3TC-EFV-TDF [reference], 3TC-AZT-NVP,
3TC-EFV-AZT, or other), earliest CD4 count (<200, 200–499, or 500+ cells/mm3 [reference]),
having one or more HIV transmission risk factor identified on the case report (yes, no [refer-
ence], or unknown), and receipt of ART from multiple treatment facilities (yes, no [reference],
or unknown). A parsimonious model was also fitted using a stepwise backwards-elimination
variable selection procedure (based on Akaike’s information criterion); however, the results of
the parsimonious model were similar to the results of the full model (i.e., all variables were
retained), and therefore only the full model results were presented. To examine the effect of
geographic residence, we ran the full models with and without department of residence and
the findings remained the same.
The associations were described as odds ratios (OR) and their respective 95% confidence
intervals (CI) at the p<0.05 significance level. SAS software version 9.4 was used for all data
analyses [14]. We plotted the prevalence of delayed viral suppression by geographic depart-
ment using the Geographic Information Systems (GIS) software, ArcGIS Pro 2.3.3 [15].
Results
Between 2013 and 2017, 6,395 PLHIV had viral load tests documented in SALVH within 3–12
months after ART initiation; however, the results of the tests were not available for a substan-
tial number of individuals (n = 3,027), presumably due to reporting issues. We assessed
whether there were any systematic differences between the characteristics of PLHIV who had
test results reported to the SALVH surveillance system (n = 3,368) vs those who did not have
reliable test results reported to SALVH (n = 3,027) (refer to S1 Table). Of note, individuals
included in the study population were more likely to be treated with 3TC-EFV-TDF regimens
(87.9% vs 84.5%, p<0.01) and have a CD4 count<200 cells/mm3 (24.0% vs 15.1%, p<0.01).
Characteristics of study population
Among PLHIV with available viral load test results, 1,335 had a result�1,000 HIV-1 RNA
copies/mm3, indicating a prevalence of delayed viral suppression of 39.6% in this sample. A
flowchart showing the selection of the population is depicted in Fig 1. The median time to
viral load measurement was 216 days for those included in the study. The average log-trans-
formed viral load values were consistent across all months of assessment after ART initiation
(S1 Fig). Prevalence of delayed viral suppression varied across geographic departments: 54.9%
in the Nord-Ouest, 35.7% in the Nord, 30% in the Nord-Est, 33.7% in Artibonite-Centre,
42.5% in the Ouest, 36.3% in the Sud (Fig 2).
Descriptive analyses indicated that individuals who experienced delayed viral suppression
were on average younger than individuals with suppression (33.2 vs 36.3 years, p<0.01) and
more likely to be under the age of 20 years (11.7% vs 6.8%, p<0.01) when examining age
groups (Table 1). Those experiencing delayed virologic suppression were more likely to be
male (43.1% vs 39.5%, p = 0.04), diagnosed in the Ouest Department (61.1% vs 54.3%,
p<0.01), have a CD4 count test result <200 cells/mm3 (29.0% vs 20.8%, p<0.01), and to
receive ART from multiple treatment facilities (5.9% vs 3.6%, p<0.01), as compared to individ-
uals with virologic suppression. PLHIV who experienced delayed viral suppression were also
PLOS ONE Virologic suppression in Haiti
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less likely to be married (12.4% vs 15.5%, p<0.01) or have an HIV transmission risk factor iden-
tified on a case-report form (51.5% vs 55.6%, p = 0.02). The majority of PLHIV in both popula-
tions were prescribed 3TC-EFV-TDF regimens, however individuals with delayed viral
Fig 1. Selection of the study population. This figure displays the participation disposition flow for the study.
https://doi.org/10.1371/journal.pone.0240817.g001
Fig 2. Prevalence of delayed viral suppression by geographic region (department) in Haiti between 2013 and 2017.
This figure shows the prevalence of delayed viral suppression among persons newly-initiated on antiretroviral therapy
by the geographic department in which they received clinical care between 2013 and 2017. ‘Sud’ department in this
image represents Grande Anse, Nippes, Sud, and Sud-Est departments combined.
https://doi.org/10.1371/journal.pone.0240817.g002
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Table 1. Demographic and clinical characteristics of persons living with HIV in Haiti by virologic status, 2013–
2017.
Characteristic Delayed viral suppression (n = 1,335) Viral
suppression
(n = 2,033)
Global p-for difference
χ2 test
Mean (SD)
Age at HIV diagnosis (years)� 33.2 (14.0) 36.3 (13.0) <0.0001
Frequency (%)
Age at HIV diagnosis (years) <0.0001
<5 65 (4.9) 33 (1.6)
5–14 47 (3.5) 48 (2.4)
15–19 44 (3.3) 57 (2.8)
20–29 343 (25.7) 470 (23.1)
30–39 400 (30.0) 634 (31.2)
40–49 247 (18.5) 440 (21.6)
50–59 119 (8.9) 231 (11.4)
60+ 37 (2.8) 82 (4.0)
Unknown 33 (2.5) 38 (1.9)
Sex 0.0352
Female 759 (56.9) 1,230 (60.5)
Male 576 (43.1) 803 (39.5)
Marital status 0.0012
Single 278 (20.8) 374 (18.4)
Cohabitating 516 (38.7) 778 (38.3)
Married 166 (12.4) 315 (15.5)
Divorced or widowed 151 (11.3) 288 (14.2)
Unknown 224 (16.8) 278 (13.7)
Clinic department† <0.0001
Artibonite-Centre 94 (7.0) 185 (9.1)
Nord 229 (17.2) 413 (20.3)
Nord-Est 48 (3.6) 112 (5.5)
Nord-Ouest 45 (3.4) 37 (1.8)
Ouest 816 (61.1) 1,103 (54.3)
Sud 101 (7.6) 177 (8.7)
Unknown 2 (0.1) 6 (0.3)
Year of HIV diagnosis 0.0052
<2010 78 (5.8) 117 (5.8)
2010–11 84 (6.3) 116 (5.7)
2012–13 204 (15.3) 314 (15.4)
2014–15 535 (40.1) 939 (46.2)
2016 430 (32.2) 539 (26.5)
Unknown 4 (0.3) 8 (0.4)
WHO clinical stage <0.0001
I 163 (12.2) 223 (11.0)
II 369 (27.6) 440 (21.6)
III 165 (12.4) 199 (9.8)
IV 29 (2.2) 29 (1.4)
Unknown 609 (45.6) 1,142 (56.2)
Year of ART initiation 0.0225
2013 107 (8.0) 123 (6.1)
(Continued)
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suppression were more likely to receive an ART regimen other than 3TC-EFV-TDF (16.3% vs
9.4%, p<0.01). PLHIV with and without delayed viral suppression did not appear to differ with
respect to time from diagnosis to ART initiation or history or presence of TB or STIs.
Associations of demographic and clinical characteristic with delayed viral
suppression
Bivariate and multivariate results are presented in Table 2. In the multivariable analysis, age,
clinic department, ART regimen, and CD4 count remained significantly associated with
Table 1. (Continued)
Characteristic Delayed viral suppression (n = 1,335) Viral
suppression
(n = 2,033)
Global p-for difference
χ2 test
2014 108 (8.1) 153 (7.5)
2015 374 (28.0) 652 (32.1)
2016 746 (55.9) 1,105 (54.4)
ART regimen <0.0001
3TC-AZT-NVP 79 (5.9) 54 (2.7)
3TC-EFV-AZT 57 (4.3) 73 (3.6)
3TC-EFV-TDF 1,118 (83.7) 1,841 (90.6)
Other 81 (6.0) 65 (3.0)
Earliest CD4 T cell count <0.0001
<200 387 (29.0) 423 (20.8)
200–499 389 (29.1) 660 (32.5)
500+ 274 (20.5) 566 (27.8)
Unknown 285 (21.3) 384 (18.9)
History/presence of TB 0.0828
No 803 (60.1) 1,299 (63.9)
Yes 62 (4.6) 91 (4.5)
Unknown 470 (35.2) 643 (31.6)
History/presence of STIs 0.5356
No 663 (49.7) 990 (48.7)
Yes 288 (21.6) 472 (23.2)
Unknown 384 (28.8) 571 (28.1)
Any risk factor identified 0.0196
No 647 (48.5) 902 (44.4)
Yes 688 (51.5) 1,131 (55.6)
Multiple ART facilities 0.0019
No 1,256 (94.1) 1,959 (96.4)
Yes 79 (5.9) 74 (3.6)
Time to ART 0.0013
<1 year of diagnosis 945 (70.8) 1,409 (69.3)
�1 year of diagnosis 353 (26.4) 599 (29.5)
Unknown 37 (2.8) 25 (1.2)
SD, standard deviation; WHO, World Health Organization; ART, antiretroviral therapy; 3TC, lamivudine; AZT,
zidovudine; NVP, nevirapine; EFV, efavirenz; TDF, tenofovir; TB, tuberculosis; STIs, sexually transmitted infections.
�Evaluated using t-test.
†Sud department is combined and includes Sud, Sud-Est, Grande-Anse, Nippes.
https://doi.org/10.1371/journal.pone.0240817.t001
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Table 2. Odds Ratios (OR) and 95% Confidence Intervals (CI) of demographic and clinical characteristics associ-
ated with delayed viral suppression in Haiti, 2013–2017.
Characteristic Unadjusted ORs Adjusted ORs
(95% CI) (95% CI)
Age at HIV diagnosis (years) 0.98 (0.98; 0.99) 0.99 (0.98; 0.99)
Sex
Male vs. female 1.16 (1.01;1.34) 1.14 (0.98; 1.33)
Marital status
Cohabitating vs. single 0.89 (0.74; 1.08) 1.10 (0.90; 1.36)
Married vs. single 0.71 (0.56; 0.91) 0.87 (0.66; 1.13)
Divorced/widowed vs. single 0.71 (0.55; 0.91) 0.91 (0.68; 1.21)
Unknown vs. single 1.08 (0.86; 1.37) 1.13 (0.88; 1.46)
Clinic department�
Artibonite-Centre vs. Ouest 0.69 (0.53; 0.90) 0.74 (0.56; 0.99)
Nord vs. Ouest 0.75 (0.62; 0.90) 0.80 (0.64; 0.99)
Nord-Est vs. Ouest 0.58 (0.41; 0.82) 0.61 (0.42; 0.89)
Nord-Ouest vs. Ouest 1.64 (1.05; 2.56) 1.45 (0.90; 2.35)
Sud vs. Ouest 0.77 (0.59; 1.00) 0.84 (0.63; 1.12)
Unknown vs. Ouest 0.45 (0.09; 2.24) 0.45 (0.09; 2.32)
Year of HIV diagnosis
2010–11 vs. <2010 1.09 (0.73; 1.62) 1.22 (0.79; 1.86)
2012–13 vs. <2010 0.98 (0.70; 1.36) 1.02 (0.69; 1.49)
2014–15 vs. <2010 0.86 (0.63; 1.16) 0.95 (0.63; 1.42)
2016 vs. <2010 1.20 (0.88; 1.64) 1.23 (0.76; 2.01)
Unknown vs. <2010 0.75 (0.22; 2.58) -†
WHO clinical stage
II vs. I 1.15 (0.90; 1.47) 1.20 (0.93; 1.57)
III vs. I 1.13 (0.85; 1.51) 1.10 (0.81; 1.51)
IV vs. I 1.37 (0.79; 2.38) 1.48 (0.82; 2.67)
Unknown vs I 0.73 (0.58; 0.91) 0.80 (0.62; 1.04)
Year of ART initiation
2014 vs. 2013 0.81 (0.57; 1.16) 0.91 (0.58; 1.42)
2015 vs. 2013 0.66 (0.49; 0.88) 0.90 (0.60; 1.35)
2016 vs. 2013 0.78 (0.59; 1.02) 0.99 (0.64; 1.55)
ART regimen
3TC-AZT-NVP vs. 3TC-EFV-TDF 2.41 (1.69; 3.43) 2.18 (1.48; 3.23)
3TC-EFV-AZT vs. 3TC-EFV-TDF 1.29 (0.90; 1.83) 1.41 (0.96; 2.07)
Other vs. 3TC-EFV-TDF 2.14 (1.52; 3.02) 1.66 (1.14; 2.43)
Earliest CD4 T cell count
<200 vs. 500+ 1.89 (1.55; 2.31) 1.90 (1.51; 2.39)
200–499 vs. 500+ 1.22 (1.01; 1.47) 1.30 (1.05; 1.61)
Unknown vs. 500+ 1.53 (1.24; 1.89) 1.64 (1.30; 2.07)
Any risk factor identified
Yes vs. no 0.85 (0.74; 0.97) 0.96 (0.83; 1.12)
Multiple treatment facilities
Yes vs. no 1.67 (1.20; 2.30) 1.28 (0.88; 1.85)
Time to ART
� 1 year of diagnosis vs. <1 year of diagnosis 0.88 (0.75; 1.03) 0.94 (0.69; 1.28)
(Continued)
PLOS ONE Virologic suppression in Haiti
PLOS ONE | https://doi.org/10.1371/journal.pone.0240817 October 29, 2020 8 / 14
delayed viral suppression at the p<0.05 level. Age was inversely correlated with delayed viral
suppression, for which we observed a 1% decrease in the likelihood of delayed suppression for
each one-year increase in age (OR = 0.99; 95% CI 0.98–0.99) (Table 2). PLHIV diagnosed in
the Artibonite-Centre, Nord, and Nord-Est departments had 26%, 20%, and 39% decreased
odds of delayed suppression, respectively, as compared to PLHIV diagnosed in the Ouest
department. The demographic characteristics of sex and marital status were not significantly
associated with viral suppression status in the multivariable models.
Individuals treated with 3TC-AZT-NVP or an alternative (“other”) regimen had approxi-
mately 2.2 (OR = 2.18; 95% CI 1.48–3.23) and 1.7 (OR = 1.66; 95% CI 1.14–2.43) times
increased odds of delayed viral suppression, respectively, as compared to individuals treated
with 3TC-EFV-TDF. Compared to individuals in the highest CD4 category (�500 cells/mm3),
individuals in the lowest category (<200 cells/mm3) had 1.9 times increased odds of delayed
viral suppression (OR = 1.90; 95% CI 1.51–2.39). Individuals in the second lowest CD4 cate-
gory (200–499 cells/mm3) had 1.3 times increased odds of delayed viral suppression
(OR = 1.31; 95% CI 1.06–1.61) compared to individuals in the highest CD4 category. Interest-
ingly, individuals with missing CD4 values performed similarly to those within the lowest CD4
category compared to those within the highest category (OR = 1.92; 95% CI 1.53–2.40). Indi-
viduals with missing data on time to ART had higher odds of delayed viral suppression com-
pared to individuals who initiated ART within one year of diagnosis (OR = 2.02; 95% CI 1.04–
3.93). WHO clinical stage, years of HIV diagnosis or ART initiation, having a risk factor iden-
tified, and receipt of ART from multiple facilities were not statistically significantly associated
with delayed viral suppression in the final multivariable models.
Discussion
The purpose of this study was to estimate the prevalence of and determine the demographic
and clinical characteristics associated with delayed viral suppression in a sample of PLHIV
receiving first line ART in Haiti. The results indicated virologic outcomes varied according to
age, clinic department, ART regimen, and CD4 count. Delayed viral suppression occurred in
nearly 40% of this sample, which is slightly higher than current estimates of this outcome in
Haiti. In the analysis conducted by Jean Louis et al., 32.4% of individuals experienced a viral
load level�1,000 copies/mL after 6–60 months or more on ART [6]. Most individuals in that
study (84%) were receiving ART for at least 12 months prior to viral load assessment [6], and
the analysis did not account for regimen changes during the follow-up period, which could
indicate delays in viral suppression or virologic failure. In considering the geographic distribu-
tion of viral suppression status, we observed the highest prevalence of delayed suppression
among patients receiving care at clinics located in the Ouest (42.5%) and Nord-Ouest depart-
ments (54.9%); however, only the Ouest department remained significantly associated with
increased odds of delayed suppression after multivariable adjustment.
Table 2. (Continued)
Characteristic Unadjusted ORs Adjusted ORs
(95% CI) (95% CI)
Unknown vs. <1 year of diagnosis 2.21 (1.32; 3.69) 2.02 (1.04; 3.93)
OR, odds ratio; CI, confidence interval; WHO, World Health Organization; ART, antiretroviral therapy; 3TC,
lamivudine; AZT, zidovudine; NVP, nevirapine; EFV, efavirenz; TDF, tenofovir.
�Sud department is combined and includes Sud, Sud-Est, Grande-Anse, Nippes.
†Missing values were dropped due to removal of missing values in another data field.
https://doi.org/10.1371/journal.pone.0240817.t002
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The geographic variability identified in our analysis could perhaps be due to surveillance
bias and regional differences in resources. Clinicians in the Ouest department, where the capi-
tal Port-au-Prince and the majority of HIV facilities are located, may have been more likely to
order viral load tests for those suspected of virologic failure, allowing for a higher rate of detec-
tion than may be possible in regions with less resources. Although not statistically significant
in the multivariable model, the prevalence of delayed viral suppression was highest in the
Nord-Ouest department and this finding is similar to results presented in another study assess-
ing rates of mortality and loss to follow-up after ART initiation by specific HIV facility in Haiti
[4]. That study reported higher rates of mortality in the main HIV facility in the Nord-Ouest
(9.5 deaths per 100 person years in the first year following ART initiation) versus the Ouest
(1.6–8.3 deaths per 100 person years) [4]. Rates of loss to follow-up were not noticeably higher
in the Nord Ouest facility, however, according to the same study.
In addition to receiving care in the Ouest department, younger patients were more likely to
experience delayed viral suppression. Delays in viral suppression on first-line ART among
younger PLHIV may be linked to issues of adherence or pretreatment drug resistance among
persons with perinatal exposure to HIV in Haiti, where rates of mother-to-child transmission
in the early years of the epidemic were reportedly as high as 27% [16]. According to the
WHO’s recent report on HIV drug resistance, the prevalence of pretreatment resistance is dis-
proportionally higher among children infected through mother-to-child-transmission [17]. In
contrast with our findings, however, Jean Louis et al reported younger age was not associated
with long-term viral suppression status [6]. There was no association between marital status
and sex with viral suppression in this study after multivariable adjustment. The lack of a statis-
tically significant difference in treatment outcomes between males and females stands in con-
trast to previous studies in Haiti. In Jean Louis et al., males were 20% less likely to be virally
suppressed after at least 6 months on ART [6] and in McNairy et al., male sex was associated
with higher HIV mortality after 12 months on ART [4]. While it is possible that males may
have poorer health outcomes in the long term due to issues such as adherence or loss to fol-
low-up [4, 6], our study found no difference in early virologic outcomes by sex after multivari-
able adjustment.
The clinical factors associated with increased odds of delayed viral suppression in our anal-
ysis were a CD4 count<200 cells/mm3, an ART regimen consisting of 3TC-AZT-NVP and
receipt of ART from multiple treatment facilities. The association between delayed suppression
and lower CD4 counts is consistent with previous studies in Haiti and in other low resource
environments [6, 8, 18]. Missing CD4 counts appear to be an indicator of poorer health status
given that they were associated with delayed viral suppression. While most individuals in our
study were receiving the current recommended ART regimen (3TC-EFV-TDF), individuals
on alternative regimens were more likely to experience delayed suppression. Notably, the ART
regimen 3TC-AZT-NVP was linked to the greatest odds of delayed viral suppression in this
study when compared to the 3TC-EFV-TDF regimen. This first-line ART regimen was simi-
larly associated with delayed viral suppression in the study conducted by Jean Louis et al. Dif-
ferences in virologic outcomes on 3TC-AZT-NVP vs 3TC-EFV-TDF regimens may be
explained by the comparative effectiveness of the NRTI backbone [AZT vs TDF] or the
NNRTIs [\NVP vs EFV]. Previous studies comparing the efficacy and effectiveness of TDF- vs
AZT-based regimens have reported better performance of TDF with respect to higher immu-
nologic recovery [19], fewer drug substitutions and lower mortality [20]. Moreover, a system-
atic review of the effectiveness of EFV versus NVP NNRTI therapies reported minimal
difference in likelihood of viral suppression, however, the development of drug resistance was
slightly higher for individuals who received NVP [21]. Poorer efficacy and effectiveness of
AZT or NVP alone, or in combination, may explain the poorer virologic outcomes observed
PLOS ONE Virologic suppression in Haiti
PLOS ONE | https://doi.org/10.1371/journal.pone.0240817 October 29, 2020 10 / 14
among persons receiving 3TC-AZT-NVP regimens in this study. Receipt of ART from multi-
ple treatment facilities was positively correlated to delayed viral suppression in our study, sug-
gesting that transfers between clinics could be a signal for medication shopping due to failed
treatments or fragmented care.
This analysis was the first to assess the virologic outcomes of PLHIV outside of the capital
of Port-au-Prince and to report variability by geographic regions (departments). Moreover,
this analysis was also the first to assess delayed viral suppression among PLHIV newly-initiated
on ART in Haiti, which provides important insight for informing national treatment guide-
lines for first-line ART. Previous studies have reported that earlier detection of unsuppressed
viral load is highly correlated with long-term virologic failure [22, 23] and significantly reduces
delays in switching to second-line therapies [24]. Earlier detection of delayed viral suppression
and switch to second-line therapy was previously found to increase the probability of survival
among PLHIV in Haiti from 88% to 93% [25].
This study had limitations. First, according to the surveillance system, viral load tests were
performed for only 35.8% of PLHIV newly-initiated on ART between 2013 and 2016.
Although it is possible additional tests were performed but not reported to SALVH, this find-
ing raises doubt concerning the representativeness of this sample population of PLHIV on
ART. Further, records for a significant proportion of individuals (46.3%) who met the study
criteria (i.e. ART initiation between 2013 and 2016 followed by a viral load test within 3–12
months after) had unknown virologic status in the national surveillance system. This led us to
exclude these individuals from the primary analysis and called into question potential selection
bias. Our bias analysis indicated that individuals included in the study were more likely to be
treated with 3TC-EFV-TDF and have a CD4 count below 200 cells/mm3. While having a low
CD4 count was associated with increased risk of delayed viral suppression in the primary anal-
ysis, treatment with 3TC-EFV-TDF was associated with reduced risk, and therefore these dif-
ferences were not systematically associated with the outcome. Another limitation of the
current analysis was the lack of a baseline viral load test and the use of only a single viral load
measurement to classify viral suppression. Ideally, two viral load test results would be used to
confirm a diagnosis of viral failure, however, baseline and/or follow-up testing was not suffi-
ciently available in this sample to be included in the analysis. Additionally, per our inclusion
criteria of viral load assessment between 3 and 12 months of ART initiation, we found fewer
samples tested in the 3-6-month window. Despite this, findings from the viral load boxplot
demonstrated consistent viral load values across all months of assessment. Therefore, it is
unlikely that assessment within the 3-6-month window led to a biased assessment of delayed
viral suppression in this analysis.
The HIV treatment guidelines in Haiti, as of 2018, recommend performing a second viral
load test six months after the initial test for individuals with an initial viral load�1,000 copies/
mL to confirm a diagnosis of virologic failure. However, because multiple assessments were
not sufficiently available for consideration in this analysis, we opted to examine delayed viral
suppression instead. Further, the proportion of missing data on some covariates ranged from
14.9% to 35.9% which limited their utility in the analyses. Of note, information on the history
or presence of TB or STIs was significantly under-reported (33.0% and 28.3% missing, respec-
tively). This may explain the lack of an association between virologic outcomes and the history
of or comorbid tuberculosis, the latter of which was previously identified as a factor for delayed
viral suppression in this population [6]. Additionally, WHO clinical stage data was missing for
approximately 35.9% of individuals, which likely explains the lack of association between
delayed viral suppression and more severe infection stages. Further, limited or no data were
available in SALVH on the mode of HIV transmission, treatment adherence or prior treatment
exposure, which have previously been linked to delays in viral suppression.
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Conclusions
In conclusion, this study was the first to assess factors associated with delayed viral suppression
among PLHIV initiating first-line ART outside of Port-au-Prince, Haiti using the national
centralized surveillance system. As a result, we identified opportunities for public health action
to inform national treatment guidelines and improve patient care. Virologic status differed by
various demographic and clinical factors, including age, clinic department, ART regimen,
CD4 count, and receipt of ART from multiple treatment facilities. The alternative ART regi-
men 3TC-AZT-NVP was strongly associated with poorer virologic outcomes in the present
study, and therefore we recommend more frequent viral load testing for individuals receiving
these first-line therapies. Strategies to improve ART outcomes, such as more frequent viral
load testing, drug resistance testing, and ART adherence counseling, are recommended for all
PLHIV with delayed suppression at the first viral load assessment. Additionally, given that
missingness was associated with poorer health outcomes in this analysis, sustained efforts to
maintain clinical data flows into SALVH are needed. Furthermore, future studies should inves-
tigate the underlying socio-ecological, behavioral and/or healthcare system factors contribut-
ing to poorer ART outcomes by clinic department.
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9. Hare AQ, Ordóñez CE, Johnson BA, del Rio C, Kearns RA, Wu B, et al. Gender-Specific Risk Factors
for Virologic Failure in KwaZulu-Natal: Automobile Ownership and Financial Insecurity. AIDS and
Behavior. 2014; 18: 2219–2229. https://doi.org/10.1007/s10461-014-0849-1 PMID: 25037488
10. Delcher C, Puttkammer N, Arnoux R, Francois K, Griswold M, Zaidi I, et al. Validating Procedures used
to Identify Duplicate Reports in Haiti’s National HIV/AIDS Case Surveillance System. J Registry Manag.
2016; 43: 10–15. PMID: 27195993
11. Smit PW, Sollis KA, Fiscus S, Ford N, Vitoria M, Essajee S, et al. Systematic Review of the Use of Dried
Blood Spots for Monitoring HIV Viral Load and for Early Infant Diagnosis. Paxton WA, editor. PLoS
ONE. 2014; 9: e86461. https://doi.org/10.1371/journal.pone.0086461 PMID: 24603442
12. Pannus P, Claus M, Gonzalez MMP, Ford N, Fransen K. Sensitivity and specificity of dried blood spots
for HIV-1 viral load quantification: A laboratory assessment of 3 commercial assays. Medicine. 2016;
95: e5475. https://doi.org/10.1097/MD.0000000000005475 PMID: 27902602
13. World Health Organization. ANNEX 10, WHO clinical staging of HIV disease in adults, adolescents and
children. Geneva, Switzerland; 2016. Available: https://www.ncbi.nlm.nih.gov/books/NBK374293/
14. SAS Institute. SAS/STAT 9.4 User’s Guide. Cary, NC: SAS Institute, Inc.; 2015.
15. ESRI. ArcGIS Pro 2.3. Redlands, CA: Environmental Systems Research Institute.; 2019.
16. Jean SS, Pape JW, Verdier RI, Reed GW, Hutto C, Johnson WD, et al. The natural history of human
immunodeficiency virus 1 infection in Haitian infants. Pediatr Infect Dis J. 1999; 18: 58–63. https://doi.
org/10.1097/00006454-199901000-00014 PMID: 9951982
17. Haile-Selassie H, World Health Organization, World Health Organization, Department of HIV/AIDS,
Centers for Disease Control and Prevention (U.S.), Global Fund to Fight AIDS T and Malaria, et al.
WHO HIV drug resistance report 2017. 2017. Available: http://apps.who.int/iris/bitstream/10665/
255896/1/9789241512831-eng.pdf
PLOS ONE Virologic suppression in Haiti
PLOS ONE | https://doi.org/10.1371/journal.pone.0240817 October 29, 2020 13 / 14
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